PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

"The Report PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

​PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

Summary
GlobalData estimates sales of HF therapeutics to be approximately $3.7B across the 7MM in 2016, encompassing the US, the five major European markets (5EU: France, Germany, Italy, Spain and UK), and Japan.

Get Sample copy of this Report @​ https://www.marketresearchreports.biz/sample/sample/1335051

By 2026, GlobalData expects the HF market to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of $16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of a new acute HF therapy, this figure is expected to increase slightly to 98.7% by 2026. GlobalData expects uptake of Novartis Entresto will be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of $8.6B in 2022.

Key Questions Answered
- The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by GlobalData provide insights and highlight opportunities for drug developers.
- The HF market is crowded with cheap, generic, me-too drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- Will Entresto become the new standard-of-care in the chronic HF market? What are the main barriers a new therapy faces when entering the HF market?

View Report @ ​https://www.marketresearchreports.biz/reports/1335051/pharmapoint-heart-failure-global-market-research-reports

Scope
- Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM HF therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Browse more Pharmaceutical Market Research Reports @ https://www.marketresearchreports.biz/category/38

Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 10
2 Heart Failure: Executive Summary 12
2.1 The HF Market Will Exhibit Strong Growth Between 2016 and 2026 12
2.2 Label Expansion to HF with Preserved Ejection Fraction Will Fuel Market Growth 14
2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline 15
2.4 Opportunities Remain for All Aspects of HF, But What the Market Really Needs Is a Transformational Therapy 16
2.5 Entresto Will Dominate the HF Market 16
2.6 What Do Physicians Think? 17

Request for Enquiry @​ https://www.marketresearchreports.biz/sample/enquiry/1335051

3 Introduction 20
3.1 Catalyst 20
3.2 Related Reports 20
4 Disease Overview 21
4.1 Etiology and Pathophysiology 21
4.1.1 Etiology 21
4.1.2 Pathophysiology 23
4.1.3 Biomarkers/Targets of Interest 25
4.2 Classification or Staging Systems 26
4.3 Symptoms 27
4.4 Prognosis 28
4.5 Quality of Life 29

About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact us

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.